Abstract
JAK2 V617F gene mutation positive myeloproliferative neoplasms (MPN) consists of polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). This article focuses on their risk scoring systems and treatment including first-and second-line therapies, JAK2 inhibitors, cytoreduction, antifibrosis and other single-agent or combination therapy. Key words: Myeloproliferative neoplasms; JAK2 V617F gene mutation; Therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
